372 results about "Therapeutic embolization" patented technology

Embolism protection devices can be formed with a biocompatible expandable polymer that can expand upon release within a patient's vessel. Upon release, the structure can be configured to filter flow through the vessel. The material of the embolism protection devices can release one or more biologically active agents, such as a thrombolitic agent, including, for example, tPA. Alternatively or additionally, the embolism protection device can be connected to a tether that elutes one or more biologically active agents.

The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present, invention relates to a process for producing the polyvinylalcbhol microspheres.

The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and / or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

The present invention relates to porous embolization devices, methods of making and using the devices as well as methods and devices to hydrate and deliver embolization particle(s).

The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) physically linked to a transfection agent for use in embolization gene therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present invention relates to a process for producing the polyvinylalcohol microspheres.

The invention concerns a radiopaque, non-biodegradable, water-insoluble iodinated benzyl ether of poly(vinyl alcohol) consisting of a PVA having covalently grafted thereon iodinated benzyl groups comprising 1-4 iodine atoms per benzyl group, a process for preparing the same comprising reacting a 0-100% hydrolyzed PVA with a iodinated benzyl derivative comprising 1-4 iodine atoms per benzyl group in a polar aprotic solvent in the presence of a base in anhydrous conditions. Said iodo-benzylether-PVA is particularly useful as embolic agent in an injectable embolizing composition. The invention also concerns an injectable embolizing composition comprising said iodo-benzylether-PVA and capable of forming a cohesive mass upon contact with a body fluid by precipitation of the iodo-benzylether-PVA. Said injectable embolizing composition is particularly useful for forming in-situ a cohesive mass in a blood vessel or into a tumor. The invention further concerns a coating composition containing said iodo-benzylether-PVA and capable of forming a radiopaque coating on a medical device. The invention further concerns particles formed of said iodo-benzylether-PVA.

The invention provides an embolism material composition as well as preparation method and use thereof, the embolism material composition is prepared from reactant raw materials, wherein the reactant raw materials comprise a biocompatibility material, a roentgenopaque substance and a magnetic resonance imaging substance, the roentgenopaque substance and the magnetic resonance imaging (MRI) substance are covered by the biocompatibility material. The embolism material composition not only can be directly detected by an X-ray image device, but also can be directly detected by the MRI, so that a doctor can select a detection method according to self condition of a patient and the medical device condition.

The invention discloses an apparatus and a method for processing tumor image information processing based on digital virtual organ. The apparatus comprises: a body imaging device; image sequence processing device; body organ histomorphology images database; a device for extracting characteristics of healthy persons and patients and merging three dimensional reconstructed multi-model image data; body organization physiological and pathological database and embolism chemotherapy relevant operation simulation software. The method comprises: getting images sequence with organ internal channel information; processing the images sequence and creating virtual organs with organization structure information; extracting characteristics from human organ histomorphology images database and patients' organs image data, having three dimensional re-build multi-model image data merge, and establishing virtual organs.

Implantable therapeutic devices and methods for endovascular placement of devices at a target site, such an opening at a neck of an aneurysm, are disclosed. Selected embodiments of the present technology have closures (102) that at least partially occlude the neck of an aneurysm to stabilize embolic or coagulative treatment of the aneurysm. In one embodiment, for example, an aneurysm closure device comprises a closure structure (102) and a supplemental stabilizer (103). The closure structure can have a curved portion configured to extend along a first vessel, such as a side branch of a bifurcated vessel that extends along a lateral axis (T). The supplemental stabilizer extends from the closure structure along a longitudinal axis (L) transverse to the lateral axis of the first vessel. The supplemental stabilizer is configured to exert an outward force against a second vessel, such as a parent vessel, that extends transversely to the first vessel.

The present invention provides a process for preparing cross-linked sodium hyaluronate microspheres capable of being adopted as an emboliaztion agent by adopting sodium hyaluronate as a raw material. The process comprises the following steps: preparing a sodium hyaluronate alkaline solution gel with a concentration of 10-30% g / ml; adding the sodium hyaluronate alkaline solution gel to an emulsifier-containing oil phase, and carrying out high speed emulsification through a shearing machine, wherein an emulsification speed is 500-2000 rpm, and a time is 10-20 min; adding a certain amount of a cross-linking agent, stirring for 4-6 h at a room temperature, carrying out a cross-linking reaction, and standing overnight after completing the reaction, wherein a mass percentage of the cross-linking agent in the oil phase is 0.2-2%; and adopting a water-soluble organic solvent to wash to remove the oil phase remained on the surface of the microspheres, and finally drying to obtain the cross-linked sodium hyaluronate microspheres. According to the present invention, the preparation process is simple; and the size of the obtained microspheres is suitable for routine blood vessel emboliaztion, and the obtained microspheres have characteristics of controllable particle size, good microsphere shape, easy screening, elasticity, expandibility, no toxic-side effect on human body, good biocompatibility, good biodegradability, and ensured clinical safety.

This relates to partially acetalized polyvinyl alcohol embolization particles suitable for implanting in the human body, to compositions containing those particles, and to methods of making and using them.

Polymeric particles are provided for use in therapeutic and / or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and / or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

The present invention includes a method for treating an aneurysm. The method includes providing a biocompatible polymeric string or hollow tube and transporting the string or hollow tube to the aneurysm. The aneurysm is filled with the string. The string is cut when the aneurysm is substantially filled.

The invention relates to a developing embolism microsphere for treating tumor diseases through minimally invasive interventional therapy and a preparation method thereof and belongs to the technical field of medical materials. A functional macromolecule with biocompatibility is formed through the cross-linking polymerization of cross-linking agent iodobenzene compound and cross-linking agent alkyl acid derivative. According to the technology provided by the invention, the defect of developing by adding a developing agent in a traditional operation embolism process is overcome, the operation risk is reduced and convenience is brought for treating tumor diseases through the minimally invasive interventional therapy; the developing microsphere produced according to the preparation process has the characteristics of blocking X ray or weakening X ray and has excellent flexibility and flexibility; and meanwhile, the traditional embolism microsphere is dyed, so that the doctor can conveniently observe in the operation process; the embolism microsphere prepared according to the process is yellow and free from dyeing treatment; the operation is simple and feasible.

The invention provides a pharmaceutical composition for treating embolism and a preparation method thereof, the pharmaceutical composition comprises a hydroxyl-contained biocompatible polymer materialand a monomer containing unsaturated double bonds and anion groups, as well as a polymer generated by polymerization reaction of an optional vinyl monomer, wherein the polymerization is initiated through free radicles, and bleomycin or pingyangmycin is combined on the anion groups of the generated polymer. The preparation method combines the bleomycin or the pingyangmycin on a carrier of the polymer, thereby being capable of fully playing the dual effects of an anti-tumor antibiotic and a hardening agent owned by the bleomycin or the pingyangmycin during the embolism treatment. The anion partof the polymer can be properly combined with the bleomycin or the pingyangmycin which is rich in amino groups, thereby not only realizing the higher drug loading, but also leading the drug in an emboliaztion agent to be exchanged by cation in human body, and further realizing the slow release. In addition, the embolic carrier of the polymer has the advantages of simple prepration technology andlow cost, thereby being applicable to large-scale industrial production.

The invention relates to a preparation method of a hydrogel rapidly crosslinked by enzyme catalysis, and application thereof. A precursor of the hydrogel consists of a mixture (hereinafter referred to as No. 1 solution) of good-biocompatibility macromonomer aqueous solution with an active phenolic hydroxyl unit and dioxygenase aqueous solution which is taken as a catalyst, and the aqueous solution of the precursor can rapidly react to form a 3D polymer cross-linked network after an oxidant (usually low-concentration oxydol, hereinafter referred to as No. 2 solution) is injected. As the No. 1 solution and the No. 2 solution have low-viscosity characteristic, are suitable for being transported and injected, and can rapidly crosslink to form a gel network, the hydrogel can be used for vascular embolization treatment, cancer treatment, family planning operation blocking agents, injectable tissue engineering scaffold materials, soft tissue fillers of human body, controlled release drug carriers, anti-adhesive membranes used in operations and the like after adding one or a plurality of components with specific properties to the No. 1 solution or the No. 2 solution or the gel network.

The invention relates to a functionalized modified polyvinyl alcohol embolic microsphere and a preparation method thereof, and belongs to the field of medical intervention treatment. The functionalized modified polyvinyl alcohol embolic microsphere is prepared by taking polyvinyl alcohol as a base material, taking amino / hydroxyl carboxylic acid derivatives / sulfonic acid derivatives capable of crosslinking after acylation as a modifying agent and performing modification. The modified microsphere prepared by the method has perfect sphere shape, uniform size, high suspending property and shape change elasticity of the polyvinyl alcohol microsphere before modification. Meanwhile, a polycarboxylic / mucopolysacchariden functional group with negative charges is introduced and can be combined with micromolecular anti-tumor medicines with positive charges, so that the microsphere has high medicine loading property. Compared with the polyvinyl chloride microsphere which is not functionalized and cannot carry medicines or the microsphere which only introduces single group with negative charges and has low medicine carrying quantity in the prior art, the microsphere increases the medicine carrying quantity and improves the controlled release capability greatly.

The invention relates to epoxy-substituted oxopyridine derivatives and their preparation method and application in medicine and concretely, relates to epoxy-substituted oxopyridine derivatives shown in the general formula (I), their preparation method, a pharmaceutical composition containing the derivatives and a use of the derivatives as therapeutic agents and especially as blood coagulation factor XIa (called as FXIa for short) inhibitors and in preparation of drugs for treating diseases such as thromboembolism. The definition of each substituent in the general formula (I) is the same as thedefinition in the specification.

The invention relates to a sodium alginate micro ball vessel suppository which contains soluble medicine, and relative preparation and application, wherein said agent can be divided into two kinds as wet ball and dry ball made from degradable biological material; said carrier comprises sodium alginate, blood serum albumin, chitose, or transparent sodium solution, via the static to be solidified with calcium ion, to be made into the micro ball at 20 mum-1000 mum. The inventive material has high mechanical strength, biological compatibility, biological degradability and stability. The invention can be used to cure the vessel suppository of variable cancers.

A new oral IR formulation in solid form for a low molecular weight thrombin inhibitor having pH dependant dissolution, characterized in that the formulation comprises a filler or a combination of fillers having disintegrant properties in an amount higher than 35% w / w of the formulation.

There is provided an ultrasonic treatment device that is minimally-invasive and that achieves embolization treatment having a high blood flow blocking effect. To this end, the ultrasonic treatment device is provided with a function to transmit to a target area of a subject both a bubble generation pulse that vaporizes a contrast agent, and a bubble generation pulse that causes the diameter of the formed bubble to increase.

The invention relates to a temperature response type injectable hydrogel and a preparation method and the usage of the injectable hydrogel; the hydrogel comprises component A, component B and water, wherein the component A is cholesterol-polyethylene glycol-cholesterol; and the component B is amination beta cyclodextrin graft hydroformylation glucan. The preparation process of the injectable hydrogel is simple and convenient, and the prepared injectable hydrogel has a certain strength and toughness as well as self-repairability; compared with the prior art, the invention improves the controllability of the performances of the hydrogel, and further improves the biocompatibility of the hydrogel; the hydrogel prepared by the invention has biodegradability and can be etabolized by human body; and the hydrogel has temperature responsiveness and injectability, and can be used for a drug carrier, embolism material and tissue engineering material.

Absorbable particles which comprises poly-4-hydroxybutyrate and / or its copolymers are formulated in injectable suspension suitable for prophylactic or therapeutic embolization, which comprises administering to a human or animal the injectable suspension process for producing particles of the poly-4-hydroxybutyrate and / or its copolymer.

Devices and methods that a variety of embolization plugs for treatment of endovascular and non-endovascular defects are disclosed. The plugs have multiple braids that include an outer expandable braid and an inner expandable braid that is located inside the outer expandable braid.

Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and / or prophylaxis of thromboembolic disorders.